Tumour suppressor PTEN activity is differentially inducible by myo-inositol phosphates.
ITPP
PTEN
angiogenesis
cancer
hypoxia
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
03
02
2023
received:
15
11
2022
accepted:
10
02
2023
pubmed:
1
3
2023
medline:
15
3
2023
entrez:
28
2
2023
Statut:
ppublish
Résumé
Tumour evolution and efficacy of treatments are controlled by the microenvironment, the composition of which is primarily dependent on the angiogenic reaction to hypoxic stress. Tumour angiogenesis normalization is a challenge for adjuvant therapy strategies to chemo-, radio- and immunotherapeutics. Myo-inositol trispyrophosphate (ITPP) appears to provide the means to alleviate hypoxia in the tumour site by a double molecular mechanism. First, it modifies the properties of red blood cells (RBC) to release oxygen (O
Identifiants
pubmed: 36852461
doi: 10.1111/jcmm.17699
pmc: PMC10002956
doi:
Substances chimiques
Oxygen
S88TT14065
inositol trispyrophosphate
0
Inositol Phosphates
0
Phosphoric Monoester Hydrolases
EC 3.1.3.2
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
879-890Informations de copyright
© 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Biophys J. 2013 Feb 5;104(3):613-21
pubmed: 23442912
Oncol Lett. 2018 Mar;15(3):3437-3446
pubmed: 29467868
Cancer Cell. 2014 Nov 10;26(5):605-22
pubmed: 25517747
J Cell Mol Med. 2011 Jun;15(6):1239-53
pubmed: 21251211
Mol Cancer. 2019 Nov 11;18(1):157
pubmed: 31711497
Atherosclerosis. 2012 Apr;221(2):341-9
pubmed: 22341591
J Cell Mol Med. 2021 Apr;25(7):3284-3299
pubmed: 33624446
Trends Endocrinol Metab. 2013 Apr;24(4):184-9
pubmed: 23245767
Mol Cancer. 2019 Sep 16;18(1):139
pubmed: 31526368
Nat Rev Mol Cell Biol. 2018 Sep;19(9):547-562
pubmed: 29858604
Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15576-81
pubmed: 17028170
Biol Cell. 1993;79(1):27-35
pubmed: 8118408
Contemp Oncol (Pozn). 2018 Mar;22(1A):7-13
pubmed: 29628788
Oncogene. 2018 Aug;37(31):4239-4259
pubmed: 29713056
Chin Med Sci J. 2018 Sep 20;33(3):174-182
pubmed: 30266108
J Leukoc Biol. 1996 Dec;60(6):744-52
pubmed: 8975877
Cancer Lett. 2016 Jan 28;370(2):345-57
pubmed: 26577811
Phytomedicine. 2020 Nov;78:153318
pubmed: 32896707
Anal Biochem. 2001 Nov 15;298(2):241-5
pubmed: 11700978
J Cell Mol Med. 2023 Mar;27(6):879-890
pubmed: 36852461
Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1926-9
pubmed: 19204295
Chembiochem. 2010 Dec 10;11(18):2543-8
pubmed: 21086482
Cancer Cell. 2010 Aug 9;18(2):171-84
pubmed: 20708158
Mol Cancer Ther. 2014 Jan;13(1):165-78
pubmed: 24170768
Bioorg Med Chem Lett. 2005 Mar 15;15(6):1605-8
pubmed: 15745806
J Cell Mol Med. 2020 Feb;24(3):2272-2283
pubmed: 31957267
J Transl Med. 2020 Jan 30;18(1):45
pubmed: 32000794
Immunology. 2014 Dec;143(4):512-9
pubmed: 25196648
Cancer Cell. 2009 Mar 3;15(3):220-31
pubmed: 19249680
Sci Rep. 2021 Sep 9;11(1):18002
pubmed: 34504231
Cell. 2014 Feb 13;156(4):744-58
pubmed: 24529377
Nat Commun. 2015 Jul 31;6:7935
pubmed: 26228240
Biochim Biophys Acta. 2016 Mar;1863(3):379-381
pubmed: 26721622
J Exp Med. 2010 Oct 25;207(11):2439-53
pubmed: 20876310
Biochim Biophys Acta. 2016 Mar;1863(3):382-391
pubmed: 26079100
Cancer Res. 2000 Dec 15;60(24):7033-8
pubmed: 11156408
N Engl J Med. 2008 May 8;358(19):2039-49
pubmed: 18463380
Cancer Sci. 2011 Jul;102(7):1253-6
pubmed: 21401807
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006486
pubmed: 22393532
Biol Cell. 1993;79(3):209-18
pubmed: 7516229
Cancer Cell. 2016 Dec 12;30(6):953-967
pubmed: 27960088
Cancer Res. 2019 Aug 15;79(16):4124-4134
pubmed: 31213464
Front Immunol. 2021 Jan 20;11:613114
pubmed: 33552076
J Mol Med (Berl). 2013 Jul;91(7):883-99
pubmed: 23471434